As one of the first genomic companies with the vision of elucidating the role of genes play in human disease, Myriad used this critical information to improve patient healthcare by developing novel molecular diagnostic products. Myriad was founded in 1991 by Mark Skolnick (Professor Emeritus Department of Medical Informatics at the U), Walter Gilbert (1980 Nobel Laureate in chemistry and Professor in the Department of Molecular and Cellular Biology at Harvard University), Peter Meldrum (past President & CEO of Agridyne and Current CEO and President of Myriad Genetics, Inc.) Kevin Kimberlin of Spencer Trask & Company and Dennis Farrar (entrepreneur).
As one of the first companies to examine the relationship between genes and human disease, Myriad was created to develop genetic tests based on research from the University of Utah and has contributed to the further research and education programs at the U.
Myriad’s predictive medicine products are designed to assess an individual’s risk for developing disease, so action can be taken to prevent or delay the onset of disease. Their personalized medicine products identify a patient’s likelihood of responding to a particular therapy to ensure optimal treatment decisions. Its prognostic medicine products assess a patients risk of disease progression and recurrence, so that a physician knows how aggressively to treat the patient’s disease and in 2014 they expanded into the area of Autoimmune Diseases & Diagnostics.
Myriad believes that its predictive medicine, personalized medicine, prognostic medicine and companion diagnostic products will benefit patients worldwide by assisting physicians in guiding their healthcare decisions.